| Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma |
NCT00594516: Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain |
|
|
| Completed | 3 | 117 | US | tapentadol (CG5503) Immediate Release IR, tapentadol (CG5503) Extended Release (ER), tapentadol (CG5503) Immediate Release (IR) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH | Low Back Pain | 04/08 | 05/08 | | |
NCT00449176: A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain |
|
|
| Completed | 3 | 981 | US | tapentadol (CG5503) ER, oxycodone CR, placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH | Low Back Pain | 05/08 | 05/08 | | |
NCT00361504: A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain |
|
|
| Completed | 3 | 1123 | US, Canada | Oxycodone CR, Tapentadol (CG5503) ER, CG5503 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH | Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain, Pain | 07/08 | 07/08 | | |
NCT00487435: An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain |
|
|
| Completed | 3 | 1166 | US, Canada, RoW | Tapentadol (CG5503) Extended Release (ER) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH | Pain, Osteoarthritis, Low Back Pain | 06/09 | 06/09 | | |
NCT01063868: A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN) |
|
|
| Terminated | 3 | 47 | US | Tapentadol extended release (ER), Oxycodone controlled release (CR) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH | Diabetic Neuropathy, Painful, Diabetic Polyneuropathy | 04/10 | 06/10 | | |
NCT00983385 / 2009-010427-12: Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics |
|
|
| Completed | 3 | 208 | Europe, RoW | Tapentadol PR, Palexia®, Nucynta®, Observation period | Grünenthal GmbH | Chronic Pain, Low Back Pain | 05/10 | 07/10 | | |
|
NCT00986258 / 2009-010428-25: Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability |
|
|
| Terminated | 3 | 136 | Europe, RoW | Tapentadol Prolonged Release, - Nucynta, - Palexia | Grünenthal GmbH | Pain, Chronic Pain, Low Back Pain, Neuropathic Pain, Nociceptive Pain | 12/10 | 01/11 | | |
|
|
